spacer
home > ebr > winter 2003 > technical and commercial due diligence in biotech transactions: doing the right things and doing them right
PUBLICATIONS
European Biopharmaceutical Review

Technical and Commercial Due Diligence in Biotech Transactions: Doing the Right Things and Doing them Right

This article argues that conducting due diligence properly to ensure that potential risks and opportunities in biotechnology transactions are fully understood is more important than ever as M&A and technology licensing activities accelerate. There are many ways to go about conducting due diligence, and the factors that determine the right way to proceed are discussed, with the pros and cons set out for taking an in-house approach, versus hiring external consultants. Whatever approach is taken, a due diligence plan is vital, given the often short timescales in which deals need to be closed. Keys to success are ensuring that an independent view is taken and that the right questions are asked, such that the answers truly help to support the investment decision. Due diligence can be an intensive and time-consuming process so the task should not be underestimated or left to the last minute - while it has costs in terms of time or professional fees, cutting corners can turn out to be far more costly.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Simon Shohet, Head of Healthcare and Life Sciences Consulting Team at Cambridge Consultants Ltd

Simon Shohet has been a strategic and commercial advisor and analyst for organisations in the biotechnology and health care industry for over 12 years. Presently, he leads the Healthcare and Life Sciences Consulting team at Cambridge Consultants Ltd (CCL), a sister company of the international management consulting firm Arthur D Little. His team works for European, US and Asia-Pacific-based corporations as well as start-ups and government agencies, helping them to gain competitive advantage through strategic exploitation of life science and biomedical technologies. Before entering consulting he held posts at the Confederation of British Industry (CBI) as a Biotechnology Policy Adviser and London Business School as a Research Fellow in technology economics. He holds a PhD in Microbiology from University College London, and a BSc from the University of Edinburgh. Simon has published numerous papers and articles in management and scientific literature.

spacer
Simon Shohet
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

BioTrinity 2020

28-29 April 2020, Digitally delivered

BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement